DNA Damage Predicts Drug Sensitivity in Breast Cancer

This article originally appeared here.
DNA Damage Predicts Drug Sensitivity in Breast Cancer
DNA Damage Predicts Drug Sensitivity in Breast Cancer

(HealthDay News) -- Accumulation of telomeric allelic imbalance is indicative of defective DNA repair and predicts sensitivity to cisplatin treatment in some patients with breast and ovarian cancers, according to a study published online March 22 in Cancer Discovery.

Nicolai J. Birkbak, Ph.D., from the Technical University of Denmark in Lyngby, and colleagues examined whether there was an association between cisplatin sensitivity and genomic signatures indicative of defective DNA repair in cancer cell lines and tumors.

The researchers found that the number of regions with allelic imbalance extending to the telomere (NtAI) was associated with cisplatin sensitivity in vitro; and in patients with triple-negative breast cancer, NtAI predicted the pathological response to preoperative cisplatin treatment. Higher levels of NtAI predicted a better initial response in patients with serous ovarian cancer. In sporadic triple-negative breast cancer and serous ovarian cancers without BRCA1 or BRCA2 mutations, there was an inverse association between BRCA1 expression and NtAI.

"Thus, accumulation of telomeric allelic imbalance is a marker of platinum sensitivity and suggests impaired DNA repair," Birkbak and colleagues conclude.

Several authors disclosed a pending patent application based on this work; scientists from Affymetrix Inc. performed tumor genotyping under a research agreement with the company.

Abstract
Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs